Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

[Reuters] – An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc’s blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by . . . → Read More: Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears with Amgen, Novartis Amgen Inc (NASDAQ:AMGN) – Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis Celgene Corporation (NASDAQ:CELG) – U.S. FDA approves Celgene drug for psoriatic arthritis